BPC-157: what the research shows, human evidence and legal status in 2026

What BPC-157 is

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide of 15 amino acids, a pentadecapeptide, whose sequence was derived from a protein found in human gastric juice. It does not occur in this exact form as a known human hormone.

Most of the published research comes from a small number of laboratories and was carried out in rodents and cell cultures, examining tendon, muscle, gut and blood-vessel injury models.

What the animal research reports

Animal studies have reported faster healing in models of tendon and ligament injury, gastrointestinal lesions and other tissue damage. These findings explain the interest in BPC-157 among athletes and in wellness clinics.

Animal results frequently fail to translate to people. Doses, injury models and outcome measures in rodents do not map directly onto human use, and many promising compounds fail when they reach controlled human trials.

Human evidence is very limited

Published human data are scarce. A 2025 IRB-approved pilot study in Alternative Therapies in Health and Medicine reported on intravenous BPC-157 in two participants, looking at blood tests and vital signs. A two-person safety pilot cannot establish safety or effectiveness.

As of this writing there are no large randomized controlled trials showing that BPC-157 treats any condition in humans. Claims that it reliably heals injuries go beyond the evidence.

FDA and compounding status in the US

BPC-157 is not an FDA-approved drug. In 2023 the FDA placed it in Category 2 of bulk substances nominated for compounding, the group that raises significant safety concerns. In 2026 the regulatory picture shifted: after nominations were withdrawn, BPC-157 and several other peptides came off the Category 2 list in April 2026.

On 23–24 July 2026 the FDA Pharmacy Compounding Advisory Committee narrowly voted 8–6, with one abstention, to recommend BPC-157 for the 503A bulks list. An advisory vote is a recommendation, not FDA approval, and it does not establish clinical benefit. FDA briefing materials flagged incomplete characterization data on impurities, aggregates, bioburden and endotoxins, and a potential for immunogenicity in injectable or nasal forms.

Outside the US, check the national medicines regulator. A compounding decision in one country does not change legal status elsewhere.

Anti-doping: prohibited at all times

BPC-157 is prohibited by the World Anti-Doping Agency under section S0, Non-Approved Substances. It is prohibited in and out of competition. USADA and Sport Integrity Australia both publish specific warnings about it. Athletes subject to testing should treat any BPC-157 product as a doping risk.

Quality concerns specific to peptides like BPC-157

The FDA has noted that peptides such as BPC-157 can be sensitive to pH, temperature, concentration and process conditions, which can lead to aggregation and degradation. That makes analytical documentation more important, not less.

For research material, look for batch-specific identity confirmation by mass spectrometry, a purity result with a stated method, and clarity on whether endotoxin, sterility and residual-solvent testing were performed. A purity percentage alone answers only one of those questions.